The Clinical Observation of Childhood Asthma Treated Leukotriene Receptor Antagonist

Objective To discussion the application and effi cacy of childhood asthma treated by montelukast. Method 97 cases of children with asthma will be randomly divided into 48 cases of conventional therapy group and conventional therapy plus montelukast group with 49 cases, and to observed in children with symptoms of acute time period and the maximal expiratory flow (PEF) increased the magnitude and class children with asthma within 6 months the cumulative inhaled corticosteroids and the total amount of the total amount of available receptor agonist, and compare the two-class treatment in children with take-off and landing a few cases. Result Two groups of asthmatic children in acute phase clinical symptoms and signs disappear time there was no signifi cant difference (P 0.05), improvement in PEF between the two groups to compare the primary-class asthma children there was no signifi cant difference (P 0.05), while in secondary and tertiary-class children with asthma there was a signifi cant difference (P 0.05); for inhalation and inhaled glucocorticoid receptor agonist dosage quick comparison, in primary-class asthma children there was no signif icant difference (P 0.05), but in secondary and tertiary-class children with asthma montelukast group signifi cantly less than the amount of the control group (P 0.05). At the same time, in the control group of secondary and tertiary-class children with asthma were 35.3% (6/18) and 25.0% (3/12) demotion treatment, and in the montelukast group data for 57.9% (11/19) and 53.8 % (7/13). Conclusion For mild persistent and moderate persistent children with asthma, montelukast added to help alleviate the condition and reduce glucocorticoid receptor agonist and the amount of β2 receptor antagonist, and for children with mild intermittent asthma had no signif icant curative effect.